# Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985

> **NCT04983238** · PHASE1,PHASE2 · COMPLETED · sponsor: **Byondis B.V.** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** BYON5667 & SYD985
- **DRUG:** Placebo & SYD985

## Key facts

- **NCT ID:** NCT04983238
- **Lead sponsor:** Byondis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-06-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983238, "Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04983238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*